Free Trial

Bayer Aktiengesellschaft Q2 2023 Earnings Report

Bayer Aktiengesellschaft logo
$4.91 -0.02 (-0.41%)
(As of 12/20/2024 05:55 PM ET)

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.33
Consensus EPS
$0.33
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.02 billion
Expected Revenue
$13.53 billion
Beat/Miss
Missed by -$1.51 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Q2 2023
Time
N/A
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Bayer Aktiengesellschaft Earnings Headlines

Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY), together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

View Bayer Aktiengesellschaft Profile

More Earnings Resources from MarketBeat

Upcoming Earnings